An interventional study of Exercise and Exercise in Myotonic Dystrophy 2, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 19th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2025, is the only one with no phase, reaches primary completion later than 10 of the 26 other live ones, and was the 32nd registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 24 is below the median of 40 across 68 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 5 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An exercise regimen (PRIME: Proximal Resistance In-House Movement Exercise) has been designed for patients with myotonic dystrophy type 2 (DM2). The hypothesis is that this patient-friendly physical therapist (PT)-guided exercise program associates with improved functional capacity and muscle composition in DM2 in this two-period two-sequence cross-over study. Thus, participant will be randomized to one of the three possible groups. Participants in GROUP A will perform exercise routine virtually under the direct supervision of a physical therapist once a week and another session on their own for the first three months, then they will continue with same exercise routine at home for the last 3 months on their own. Participants in GROUP B will perform exercise routine virtually under the direct supervision of a physical therapist twice a week for the first three months, then they will continue with same exercise routine at home for the last 3 months on their own. Participants in GROUP C will perform exercise routine on their own during the first 3 months, then they will perform exercise routine virtually under the direct supervision of a physical therapist. Each group will include around 8 participants. Duration of the study is 6 months. In addition to exercise sessions, participants will have evaluation of their strength, motor function and muscle composition at three time points: initiation, 3 months and completion of the study at 6 months. Muscle composition will be assessed by electrical impedance myography which is a portable, non-invasive, painless and non-radiation tool that applies a weak high multifrequency electrical current to the examined muscle and allows to obtain information about its composition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Exercise under the supervision of physical therapist in clinic during the first 3 months, then self-directed exercise routine for the last 3 months
Other: Exercise
Exercise under the supervision of physical therapist virtually during the first 3 months, then self-directed exercise routine for the last 3 months
Other: Exercise
Self-directed exercise routine for the first 3 months, then exercise routine under the supervision of physical therapist virtually during the last 3 months
Other: Exercise
A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated. In person exercise supervised by physical therapist and then self-directed exercise in Group A
Exercise virtually supervised by physical therapist and then self-directed for group B
Self-directed and virtually supervised exercise by physical therapist for Group C
Manual Muscle Test (MMT)
Score of manual muscle strength test scale. This is a strength exam at bedside of muscle groups
Time frame: From enrollment to the end of treatment at 6 months
Six-minute walking test
Distance in meters that subject can walk in six minutes
Time frame: From enrollment to the end of treatment at 6 months
Quantitative myometry
Muscle dynamometry of different muscle groups measured in kilograms
Time frame: From enrollment to the end of treatment at 6 months
Muscle resistance/reactance measures in ohms
using electrical impedance myography, resistance and reactance measures in ohms will be obtained simultaneously from each examined muscle
Time frame: From enrollment to the end of treatment at 6 months
Time up to go
Time in seconds from standing up, walk 3 meters, come back and sit again.
Time frame: From enrollment to the end of treatment at 6 months
10 meter walk testing
Time in seconds during a 10-meter walk.
Time frame: From enrollment to the end of treatment at 6 months
Five times sit to stand
Time in seconds to complete 5 times sit to stand.
Time frame: From enrollment to the end of treatment at 6 months
Functional gait assessment (FGA)
Assessment of balance using a scale (0-30) while walking and performing motor tasks.
Time frame: From enrollment to the end of treatment at 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.
Of 26 interventional studies with no phase under Myotonic Dystrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 32 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →